Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Point-of-Care D-Dimer Tests Exclude Deep Vein Thrombosis

By LabMedica International staff writers
Posted on 10 Nov 2010
Five point-of-care (POC) blood tests for fibrin degradation product D-dimer have been evaluated for their accuracy in diagnosing deep vein thrombosis (DVT). More...


D-dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. POC D-dimer tests enable rapid exclusion of DVT without the need to refer a patient for conventional laboratory-based D-dimer testing.

Five D-dimer tests were evaluated at the University Medical Center Utrecht, (Utrecht, the Netherlands). The scientists analyzed data of 577 prospectively identified consecutive primary care patients suspected to have DVT. The patients underwent four quantitative D-dimer tests (Vidas, Pathfast, Cardiac, and Triage) and one qualitative test (Clearview Simplify). Ultrasonography was performed as the reference method. They evaluated the tests for the accuracy of their measurements and submitted a questionnaire to 20 users to assess the user-friendliness of each test.

The Vidas D-dimer test (bioMerieux; Marcy-l'Etoile, France), combines a two-step enzyme immunoassay sandwich method with fluorescent detection. The Pathfast D-dimer test (Mitsubishi Kagaku Iatron, Inc.; Tokyo, Japan), is a chemiluminescent enzyme immunoassay, which contains two D-dimer monoclonal antibodies, one labeled with alkaline phosphatase and the other coated with magnetic particles. The Cardiac D-dimer test (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland), is based on a dual monoclonal antibody sandwich comprising a poly-streptadivin-biotin capture system with a gold particle label. The Triage D-dimer test (Biosite; San Diego CA, USA), uses single-marker fluorescence sandwich immunoassay uses the 3B6 D-Dimer antibody. The Clearview Simplify D-dimer test (Inverness Medical; Princeton, NJ, USA), is based on immunochromatography, and the test uses two D-dimer specific murine monoclonal antibodies, one of which is conjugated to colloidal gold particles.

All D-dimer tests showed negative predictive values higher than 98%. Sensitivity was high for all POC tests, with a range of 0.91 for Clearview Simplify to 0.99 for Vidas. Specificity varied between 0.39 for Pathfast and 0.64 for Clearview Simplify. The quantitative POC tests showed similar and high discriminative power for DVT. The quantitative Vidas and Pathfast devices showed limited user-friendliness for primary care, owing to a laborious calibration process and long analyzer warm-up time compared to the Cardiac and Triage. For the qualitative Clearview Simplify assay, no analyzer or calibration was needed, but interpretation of a test result was sometimes difficult because of poor color contrast. The study was published on September 15, 2010 in Clinical Chemistry.

Related Links:

University Medical Center Utrecht
bioMerieux
Mitsubishi Kagaku Iatron, Inc.
Roche Diagnostics
Biosite
Inverness Medical




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.